Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentorex SCHEMBL160519 | 0.81 | TAAR1 (0.44) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL1911099 | 0.81 | SLC6A4 (0.45) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL1471159 | 0.81 | SLC6A4 (0.45) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL11968994 | 0.81 | TAAR1 (0.44) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL12574668 | 0.81 | SLC6A4 (0.45) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL2032641 | 0.78 | CYP2D6 (0.50) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL28024684 | 0.78 | CYP2D6 (0.46) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL2031549 | 0.78 | CYP2D6 (0.50) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL9360478 | 0.77 | RIPK1 (0.45) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL21740964 | 0.77 | SLC6A4 (0.42) | ADRA2AADRA2CLMNAHIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9724276-B2 | Dental materials and method of manufacture | VALSPAR SOURCING, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150224034-A1 | DENTAL MATERIALS AND METHOD OF MANUFACTURE | VALSPAR SOURCING, INC. | 2015-08-13 | — | — | US | disclosed |
| EP-2882401-A1 | DENTAL MATERIALS AND METHOD OF MANUFACTURE | Valspar Sourcing, Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014025406-A1 | DENTAL MATERIALS AND METHOD OF MANUFACTURE | VALSPAR SOURCING, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | ADRA2A 1798/4885ADRA2C 1082/4885LMNA 4476/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | ADRA2A 1446/4885ADRA2C 956/4885LMNA 4357/4885 |
| US-20150224034-A1 | DENTAL MATERIALS AND METHOD OF MANUFACTURE | ESR1, FHIT, ESR2 | ADRA2A 2797/4885ADRA2C 3171/4885LMNA 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.